Savara (SVRA) Net Equity Issued and Repurchased (2011 - 2019)
Savara (SVRA) posted quarterly Net Equity Issued and Repurchased of $1000.0 for Q4 2019, down 91.67% year-over-year from $12000.0 in Q4 2018, and down 99.98% quarter-over-quarter from $5.7 million in Q3 2019.
Savara (SVRA) Net Equity Issued and Repurchased (2011 - 2019) Analysis & Trends
Savara (SVRA) has reported Net Equity Issued and Repurchased for 8 consecutive years, with $1000.0 the latest figure, recorded in Q4 2019.
- In Q4 2019, Net Equity Issued and Repurchased fell 91.67% year-over-year to $1000.0; the TTM figure through Dec 2020 stood at $5.7 million (down 80.86% YoY), while the FY2024 annual figure was $24.4 million, up 177.27% from the prior year.
- Net Equity Issued and Repurchased slipped to $1000.0 in Q4 2019 per SVRA's latest filing, from $5.7 million in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $19.0 million in Q2 2019 and bottomed at -$7.3 million in Q2 2016.
- Historically, Net Equity Issued and Repurchased has averaged $3.1 million across 5 years, with a median of $675000.0 in 2017.
- On a YoY basis, Net Equity Issued and Repurchased climbed as much as 89455.56% in 2016 and fell as far as 441.81% in 2016.
- Savara's Net Equity Issued and Repurchased stood at $6.6 million in 2015, then sank by 99.91% to $6000.0 in 2016, then soared by 11150.0% to $675000.0 in 2017, then plunged by 98.22% to $12000.0 in 2018, then sank by 91.67% to $1000.0 in 2019.
- Business Quant data shows SVRA's Net Equity Issued and Repurchased at $1000.0 in Q4 2019, $5.7 million in Q3 2019, and $19.0 million in Q2 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Savara | 1.11 Bn | 1.11 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 1,000.00 |
| Dec 31, 2019 | 1,000.00 |
| Sep 30, 2019 | 5.66 Mn |
| Sep 30, 2019 | 5.66 Mn |
| Jun 30, 2019 | 19.04 Mn |
| Jun 30, 2019 | 19.04 Mn |
| Mar 31, 2019 | 4.89 Mn |
| Mar 31, 2019 | 4.89 Mn |
| Dec 31, 2018 | 12,000.00 |
| Dec 31, 2018 | 12,000.00 |
| Mar 31, 2018 | 493,000.00 |
| Mar 31, 2018 | 493,000.00 |
| Dec 31, 2017 | 675,000.00 |
| Dec 31, 2017 | 675,000.00 |
| Sep 30, 2016 | 6,000.00 |
| Sep 30, 2016 | 6,000.00 |
| Jun 30, 2016 | -7.28 Mn |
| Jun 30, 2016 | -7.28 Mn |
| Mar 31, 2016 | 8.06 Mn |
| Mar 31, 2016 | 8.06 Mn |